B-cell precursor acute lymphoblastic leukemia (B-ALL) is the commonest childhood malignancy [1]. While most newly diagnosed patients can be cured, relapse outcomes remain poor, with resistant disease common [2]. Established relapse protocols, such as ALL R3, rely on highly intensive chemotherapy to induce remission but are associated with a significant risk of treatment-related mortality (TRM) [3, 4], limiting delivery of effective therapy.